[Correlation between Serum Free Light Chain and Blood Routine Parameters in Patients with Multiple Myeloma]

Prior research has shown that serum free light chain (sFLC) levels are clinically relevant in multiple myeloma (MM), but the relationship between sFLC and routine blood parameters remains unclear. It was already known that MM impacts renal function and blood parameters, but no prior work had resolved how sFLC correlates with these factors. This gap motivated a detailed investigation into how sFLC interacts with commonly measured blood and renal markers. Researchers have explored MM biomarkers, but the specific interplay with routine laboratory data had not been fully mapped. The need for accessible indicators of sFLC levels in MM patients is evident in clinical settings. Existing studies focus on sFLC as a diagnostic tool, but few address its correlation with standard blood tests. This uncertainty drove the current study to examine sFLC alongside routine blood and renal parameters. The goal is to identify practical markers that can be used in conjunction with sFLC measurements.

The aim of this study was to explore the relationship between serum free light chain (sFLC) levels and routine blood parameters in patients with multiple myeloma. The specific problem addressed is identifying which blood and renal function indicators are most closely associated with sFLC. This study sought to determine whether sFLC levels can be predicted or reflected by other measurable parameters. The motivation stems from the need for more accessible diagnostic tools in MM management. Researchers wanted to assess if sFLC could be estimated using more commonly available blood tests. The study focused on correlations with creatinine, eGFR, and other biochemical markers. The goal was to evaluate how well these parameters reflect sFLC levels in MM patients. This approach could help streamline clinical assessments and improve monitoring efficiency.

The study involved a retrospective analysis of data from 347 patients diagnosed with multiple myeloma at Sichuan People's Hospital. Researchers collected serum free light chain (sFLC), serum total light chain (sTLC), and routine blood parameters. They used Pearson or Spearman correlation coefficients to assess relationships between variables. Multiple stepwise linear regression was applied to identify key predictors of sFLC levels. The Kruskal-Wallis test was used for intergroup comparisons of blood parameters. Receiver operating characteristic (ROC) curves were generated to evaluate the diagnostic accuracy of selected parameters. The study focused on correlations between sFLC and renal and biochemical markers. The approach combined statistical modeling with clinical data to identify meaningful associations.

The strongest finding was a significant positive correlation between sFLCκ and serum total light chain κ (sTLCκ) and creatinine (Cr) levels. sFLCλ was positively correlated with serum total light chain λ (sTLCλ) and eGFR. Multivariate regression showed that sFLCκ was influenced by Cr and sTLCκ, while sFLCλ was influenced by eGFR and sTLCλ. The sFLCκ/λ ratio was primarily predicted by the sTLCκ/λ ratio. The Kruskal-Wallis test confirmed that these parameters effectively reflected sFLC levels. ROC curve analysis indicated that creatinine, sTLCκ, eGFR, sTLCλ, and sTLCκ/λ had diagnostic value for sFLC abnormalities. The area under the curve (AUC) ranged from 0.684 to 0.875 for these parameters. These results suggest that routine blood and renal markers can serve as indicators of sFLC levels.

The authors proposed that serum total light chain (sTLC) parameters combined with renal function markers can reflect sFLC levels in MM patients. They suggested that sTLCκ and creatinine are useful indicators for sFLCκ levels. Similarly, sTLCλ and eGFR were proposed as indicators for sFLCλ levels. The sFLCκ/λ ratio was estimated to be best predicted by the sTLCκ/λ ratio. The study concluded that these correlations could aid in clinical assessments of MM patients. The findings suggest that routine blood tests can provide insights into sFLC status. The authors emphasized that these results could improve monitoring strategies for MM patients. They proposed that integrating sTLC and renal markers could enhance diagnostic accuracy.